MarketCapExport financials
Revolution Medicines (RVMD)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Revolution Medicines Income Statement 2025-2011 | RVMD
Brief overview of profit and loss at Revolution Medicines
The conclusions below are based on five years of reported results. Revenue reported by Revolution Medicines was $20.2 million at the beginning of the period and $11.6 million at the end. The total change was −42.6%, with a CAGR of approximately −10.5%. The business finished the period with a smaller revenue base.
Over the period, EBITDA shifted from −38.6 million dollars to −482 million dollars, a change of −1150.2%. Operating performance weakened relative to revenue. EBITDA margin was −191.2% at the start and −4163.6% at the end. A lower EBITDA share weakens the quality of the result.
Comparing the endpoints shows a move from −41.8 million dollars to −436 million dollars. Profitability deteriorated further over the five years.
Financial takeaway
The financial trajectory is weak and requires a cautious interpretation. The main areas of concern are weaker operating efficiency, a low EBITDA margin and declining net profitability. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Revolution Medicines
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
19.6 B | 6.77 B | 3.44 B | 1.99 B | 1.57 B | 2.31 B | - | - | - | - | - | - | - | - | - |
Shares |
190 M | 168 M | 113 M | 80.6 M | 72.8 M | 54.9 M | - | - | - | - | - | - | - | - | - |
Historical Prices |
103 | 40.4 | 30.4 | 24.6 | 21.5 | 42.1 | - | - | - | - | - | - | - | - | - |
Net Income |
-1.13 B | -600 M | -436 M | -249 M | -187 M | -108 M | -47.7 M | -41.8 M | -31.1 M | - | - | - | - | - | - |
Revenue |
- | - | 11.6 M | 35.4 M | 29.4 M | 43 M | 50 M | 20.2 M | - | - | - | - | - | - | - |
Operating Income |
-1.18 B | -690 M | -487 M | -258 M | -188 M | -111 M | -54.1 M | -40.3 M | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | 12 K | 71 K | 106 K | 116 K | - | - | - | - | - | - | - |
EBITDA |
-1.17 B | -683 M | -482 M | -254 M | -185 M | -108 M | -50.8 M | -38.6 M | -29.8 M | - | - | - | - | - | - |
Operating Expenses |
1.18 B | 690 M | 499 M | 294 M | 217 M | 154 M | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
195 M | 97.3 M | 75.6 M | 40.6 M | 30.4 M | 21.4 M | 12.4 M | 9.41 M | 4.54 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Revolution Medicines
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
215 M | 211 M | 198 M | 1.47 M | 189 M | 189 M | 188 M | 2.16 M | 167 M | 165 M | 165 M | 9.45 M | 109 M | 107 M | 107 M | 2.88 M | 84.7 M | 74.3 M | 74.2 M | 338 K | 73.5 M | 73.4 M | 70.4 M | 3.84 M | 64.9 M | 58.8 M | 29.3 M | 3.29 M | 2.81 M | 2.72 M | 2.64 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-407 M | -644 M | -454 M | -365 M | -305 M | -248 M | -213 M | -195 M | -156 M | -133 M | -116 M | -162 M | -108 M | -98.3 M | -98.3 M | -56.5 M | -73.3 M | -61.2 M | -57.6 M | -52.7 M | -52.9 M | -44.3 M | -37.2 M | -34.2 M | -27.2 M | -27.2 M | -21.7 M | -14.6 M | -12.8 M | -10.1 M | -10.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
198 M | - | - | - | - | - | - | - | - | - | - | 742 K | - | 3.82 M | 3.82 M | 15.3 M | 3.36 M | 9.12 M | 7.58 M | 9.46 M | 1.1 M | 8.7 M | 10.1 M | 8.75 M | 12.7 M | 10 M | 11.5 M | 12.1 M | 12.5 M | 12.3 M | 13.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
327 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
197 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-373 M | -505 M | -445 M | -362 M | -315 M | -265 M | -241 M | -216 M | -176 M | -157 M | -141 M | -180 M | -123 M | -109 M | -109 M | -61.7 M | -76.5 M | -62.1 M | -57.9 M | -52.9 M | -53.2 M | -44.5 M | -37.4 M | -34.1 M | -27.6 M | -28 M | -21.1 M | - | -13.6 M | -10.6 M | -10.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
66 K | -6 K | 117 K | - | - | -32 K | -10 K | - | 282 K | 16 K | -2.81 M | - | - | - | - | - | - | - | - | - | - | - | 12 K | 14 K | 17 K | 19 K | 21 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-373 M | -500 M | -443 M | -362 M | -315 M | -264 M | -240 M | -216 M | -175 M | -156 M | -141 M | -180 M | -123 M | -108 M | -108 M | -61.4 M | -76.2 M | -61.8 M | -57.7 M | -52.6 M | -52.9 M | -44.2 M | -37.1 M | -33.8 M | -27.3 M | -27.7 M | -20.8 M | - | -11.9 M | -9.49 M | -9.91 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
570 M | 505 M | 445 M | 362 M | 315 M | 265 M | 241 M | 216 M | 176 M | 157 M | 141 M | 181 M | 123 M | 113 M | 113 M | 77 M | 79.9 M | 71.2 M | 65.5 M | 62.4 M | 54.3 M | 53.2 M | 47.5 M | 42.8 M | 40.2 M | 38 M | 32.6 M | - | 26.1 M | 22.8 M | 23.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
153 M | 110 M | 101 M | 66.7 M | 52.8 M | 40.6 M | 35 M | 28.2 M | 24 M | 21.7 M | 22.8 M | 32.2 M | 15.5 M | 14.6 M | 14.6 M | 10.9 M | 10.4 M | 10.2 M | 9.04 M | 8.69 M | 7.79 M | 7.3 M | 6.67 M | 5.82 M | 5.34 M | 5.09 M | 5.17 M | - | 3.1 M | 2.72 M | 2.42 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Revolution Medicines (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
USA
Russia
Niderland
Israel
Spain
Germany
Australia
Britain
